Taxifolin (also known as dihydroquercetin) is a flavonoid found in various plants, including Siberian larch and milk thistle. There is a growing body of preclinical (cell and animal) research suggesting that taxifolin may have beneficial effects on mitochondrial function. Specifically, studies have shown its antioxidant properties can reduce oxidative stress in mitochondria, protect mitochondrial DNA, and support mitochondrial energy production under conditions of cellular stress.

For example, research has demonstrated that taxifolin can attenuate mitochondrial dysfunction in models of neurodegenerative diseases and diabetes by scavenging reactive oxygen species (ROS) and improving mitochondrial membrane potential. Some animal studies indicate it may help preserve mitochondrial integrity and function after injury or toxin exposure.

However, as of mid-2024, direct clinical evidence in humans is lacking. Most studies have been performed in vitro or in animal models, and there are no large-scale human trials specifically assessing taxifolin’s impact on mitochondrial health. While the mechanistic data is promising and provides a scientific rationale for its use as a mitochondrial support agent, the absence of robust clinical trials limits the strength of the evidence to a moderate level.

In summary, taxifolin is used to support mitochondrial health based on scientific (preclinical) evidence, but its efficacy in humans remains to be conclusively demonstrated.